Introduction {#Sec1}
============

Dengue is currently considered as the most important arthropod-borne viral disease \[[@CR1]\]. It is caused by dengue virus (DENV) which is transmitted by female *Aedes* mosquitoes, particularly *Aedes aegypti* \[[@CR2]\]. Using the population data of 2010 and a geostatistical model, Bhatt and colleagues estimated that approximately 390 million dengue infections occur globally every year, with 96 million symptomatic cases \[[@CR3]\]. Other studies have estimated that more than 22,000 deaths are reported annually \[[@CR4]\]. Overall, an estimated 3.9 billion people are at risk of dengue virus infection in almost 128 countries in tropical and subtropical regions \[[@CR5]\]. Dengue infection can occur with one of four DENV serotypes (DENV 1--4), and cause clinical manifestations ranging from self-limiting febrile illness, dengue fever to life-threatening dengue hemorrhagic fever which can progress to dengue shock syndrome (DSS) \[[@CR2]\]. There is no specific drug to treat DENV infection, and care is mainly supportive \[[@CR6]\]. Studies have shown a relationship between viral burden and disease severity \[[@CR7]\], and thus there is interest in compounds that have anti-DENV effects, as these may serve to reduce severity if administered early in infection.

De novo drug discovery is both prohibitively expensive \[[@CR8]\] and time consuming, and so studies in a wide range of fields have started to explore natural compounds as a way of cutting short the drug development process and additionally developing therapies that are more affordable. This study investigated the anti-DENV effects of 5 commonly used natural compounds that have been shown to have activity against other viruses, or to have the potential to have anti-viral activity, namely melatonin, α-tocopherol, folic acid, acetyl-[l]{.smallcaps}-carnitine and resveratrol.

Main text {#Sec2}
=========

Materials and methods {#Sec3}
---------------------

### Compounds {#Sec4}

Acetyl-[l]{.smallcaps}-carnitine (MW 239.70, ≥ 99% purity; Cat.No. A6706, Merck KGaA, Darmstadt, Germany) was prepared as a stock solution of 50 mM in Dulbecco's modified Eagle's medium (DMEM, Merck KGaA, Darmstadt, Germany), 10% FBS. Melatonin (MW 232.2, ≥ 98% purity; Cat.No. 444300, Merck KGaA) was prepared as a stock solution of 200 mM in 1 ml of 100% DMSO. α-Tocopherol (MW 430.71, ≥ 95.5% purity, Cat.No. 258024, Merck KGaA) was prepared as a stock solution of 100 mM in EtOH. Folic acid (MW 441.4, ≥ 97% purity, Cat.No. F7876, Merck KGaA) was prepared as a stock solution of 50 mM in 1 M NaOH. Resveratrol (MW 228.2, ≥ 98% purity, Cat No 554325, Merck KGaA) was prepared as a stock solution of 100 mM in 100% DMSO.

### Cell culture and virus {#Sec5}

The human hepatocellular carcinoma cell line HepG2 (ATCC^®^ HB-8065™) and the human embryonic kidney cell line HEK293T/17 (ATCC^®^ CRL-11268™) were cultivated in Dulbecco's modified Eagle's medium (DMEM, Merck KGaA) supplemented with 10% heat inactivated fetal bovine serum (FBS, FBS; Gibco, Merck KGaA), 100 U/ml penicillin and 100 µg/ml streptomycin (PAA Laboratories, Pasching, Austria) in a 175 cm^2^ tissue culture flask at 37  °C in 5% CO~2~. Rhesus monkey kidney cells LLC-MK2 (ATCC^®^ CCL-7™) cells were cultivated in DMEM supplemented with 5% FBS and 100 units/ml of penicillin and 100 μg/ml of streptomycin at 37 °C in an incubator with 5% CO~2~. C6/36 (Aedes albopictus, ATCC^®^ CRL-1660™) cells were cultivated in minimum essential medium (MEM; Merck KGaA) supplemented with 10% FBS, 100 units/ml of penicillin and 100 μg/ml of streptomycin at 28 °C. DENV 2 (strain 16681) was propagated in C6/36 cells and the viral titer was determined by standard plaque assay in LLC-MK2 cells essentially as described elsewhere \[[@CR9]\].

### Determination of cytotoxicity {#Sec6}

Cytotoxicity of the natural compounds in the range 0.0001--10 mM (Melatonin, ALCAR and α-tocopherol) or 0.0001--5 mM (folic acid and resveratrol) was evaluated by the MTT assay (Merck KGaA) both in infected and uninfected cells.

### Virus infection for compound screening {#Sec7}

HepG2 and HEK293T/17 cells were seeded in 12-well culture plates at a density that allowed 90% confluence to be reached within 24 h. The cells were washed in 1× PBS and incubated with 500 µl of DENV 2 containing the desired multiplicity of infection (MOI) for 2 h. HepG2 cells were infected at MOI 2 and 5, while HEK293T/7 cells were infected at MOI 0.5 and 2 at 37 °C. Mock infection (no virus) was undertaken in parallel. After 2 h of virus infection, medium was replaced with 2 concentrations of each compound in DMEM with 10% FBS and then incubated at 37 °C, 5% CO~2~. After 24-h incubation, cells were collected for determination of the degree of infectivity. For some compounds, cell supernatant was collected and levels of virus production determined by standard plaque assay.

### Flow cytometry {#Sec8}

Flow cytometry to determine percentage cell infection was undertaken using a pan specific anti-dengue E protein antibody HB114 \[[@CR10]\] as a primary antibody and a goat anti mouse IgG conjugated with FITC as secondary antibody as described elsewhere \[[@CR11]\]. Cells were run on a BD FACSCalibur (Becton--Dickinson, BD Bioscience, San Jose, CA) and data was analyzed using the CellQuest Pro software.

### Statistical analysis {#Sec9}

All data were analyzed using the GraphPad Prism program (GrapPad Software Inc., San Diego, CA). Statistical analysis of significance was undertaken by One-Way ANOVA on raw data reads using SPSS (SPSS Inc., Chicago, IL). EC~50~ values were calculated using the freeware ED50plus (v1.0) software (<http://sciencegateway.org/protocols/cellbio/drug/data/ed50v10.xls>).

Results {#Sec10}
-------

To undertake screening of compounds for anti-DENV activity, two cell lines were selected, the human embryonic kidney cell line HEK293T/17, and the human hepatocellular cell line HepG2. Both cell lines are commonly used in analysis of DENV infection, although HET293T/17 cells do not represent a normal tissue involved in DENV infection.

Five natural products (melatonin, α-tocopherol, folic acid, acetyl-[l]{.smallcaps}-carnitine and resveratrol) were selected for screening for possible anti-DENV 2 activity. All compounds were initially screened for cytotoxicity in both cell lines using the MTT assay. Cytotoxic effects were determined for both uninfected cells and DENV 2 infected cells in the range of 0.0001--10 mM (0.1--10,000 μM) for acetyl-[l]{.smallcaps}-carnitine, melatonin and α-tocopherol, and the range of 0.0001 mM (0.1--5000 μM) for folic acid and resveratrol, with treatment being undertaken for 24 h. Results showed little difference in cytotoxicity profiles of the compounds between DENV 2 infected and uninfected cells. Thus there was no cytotoxic synergism between the compounds and DENV infection. Melatonin (Fig. [1](#Fig1){ref-type="fig"}a, b), α-tocopherol (Fig. [2](#Fig2){ref-type="fig"}a, b) and acetyl-[l]{.smallcaps}-carnitine (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A, B) all showed evidence of cytotoxicity at compound concentrations of 10 mM. Folic acid (Additional file [2](#MOESM2){ref-type="media"}: Figure S2A, B) and/or the vehicle showed a slight positive effect in both HEK293T/17and HepG2 cells at concentration of 1 mM, but this was not seen at a higher concentration. Cytotoxicity was observed for resveratrol at concentrations above 0.05 mM in HEK293T/17 cells, and above 1 mM in HepG2 cells (Fig. [3](#Fig3){ref-type="fig"}a, b). Based on the cytotoxicity profiles, two concentrations were selected for each compound for assay of antiviral activity, which were 50 and 500 μM for acetyl-[l]{.smallcaps}-carnitine and melatonin, 0.5 and 1.0 mM for α-tocopherol, 0.1 and 0.5 mM for folic acid. For resveratrol which showed significant cell type variation in cytotoxicity, values of 25 and 50 μM were used for HEK293T/17 cells, and 50 and 100 μM were used for HepG2 cells. For all experiments, infections were undertaken at MOI 0.5 and 2 for HEK293T/17 cells and 2 and 5 for HepG2 cells due to different cell susceptibility to infection \[[@CR12]\].Fig. 1Effect of melatonin on DENV 2 infection of HEK293T/17 and HepG2 cells. The cytotoxicity of melatonin was assessed in **a** uninfected HEK293T/17 (left panel) and HepG2 (right panel) and **b** DENV 2 infected HEK293T/17 (left panel and HepG2 (right panel) cells. Infected and uninfected cells were incubated with various concentration of melatonin for 24 h and viability was assessed using MTT assay. The experiments were performed independently in triplicate in parallel with control treatments and mock. A negative of cells incubated with 5% DMSO in complete media was included. The standard deviation (SD) of mean are presented as error bars. **c** HEK293T/17 cells were infected with DENV 2 at MOI 0.5 and 2, and then treated with or without 50 and 500 µM of melatonin or with vehicle only. **d** HepG2 cells were infected with DENV 2 at MOI 2 and 5 and then treated with or without 50 and 500 µM of melatonin or with vehicle only. At 24 h post infection cells were analyzed by flow cytometry to determine the percentage infection. All experiments were undertaken independently in triplicate. Error bar showed mean ± SD (\*p value ≤ 0.05) Fig. 2Effect of α-tocopherol on DENV2 infection of HEK293T/17 and HepG2 cells. The cytotoxicity of α-tocopherol was assessed in **a** uninfected HEK293T/17 (left panel) and HepG2 (right panel) and **b** DENV 2 infected HEK293T/17 (left panel and HepG2 (right panel) cells. Infected and uninfected cells were incubated with various concentration of α-tocopherol for 24 h and viability was assessed using MTT assay (^‡^absorbance value of α-tocopherol was removed from all samples to calculate MTT value). The experiments were performed independently in triplicate in parallel with control treatments and mock. A negative of cells plus H~2~O only was included. The standard deviation (SD) of mean are presented as error bars. **c** HEK293T/17 cells were infected with DENV 2 at MOI 0.5 and 2, and then treated with or without 0.5 and 1 mM of α-tocopherol or with vehicle only. **d** HepG2 cells were infected with DENV 2 at MOI 2 and 5 and then treated with or without 0.5 and 1 mM of α-tocopherol or with vehicle only. At 24 h post infection cells were analyzed by flow cytometry to determine the percentage infection. All experiments were undertaken independently in triplicate. Error bar showed mean ± SD (\*p value ≤ 0.05) Fig. 3Effect of resveratrol on DENV2 infection of HEK293T/17 and HepG2 cells. The cytotoxicity of resveratrol was assessed in **a** uninfected HEK293T/17 (left panel) and HepG2 (right panel) and **b** DENV 2 infected HEK293T/17 (left panel and HepG2 (right panel) cells. Infected and uninfected cells were incubated with various concentration of resveratrol for 24 h and viability was assessed using MTT assay. The experiments were performed independently in triplicate in parallel with control treatments and mock. A negative of cells plus 5% DMSO in complete media was included. The standard deviation (SD) of mean are presented as error bars. **c** HEK293T/17 cells were infected with DENV 2 at MOI 0.5 and 2, and then treated with or without 25 or 50 μM resveratrol or with vehicle only. **d** HepG2 cells were infected with DENV 2 at MOI 2 and 5 and then treated with or without 50 or 100 μM resveratrol or with vehicle only. At 24 h post infection cells were analyzed by flow cytometry to determine the percentage infection. All experiments were undertaken independently in triplicate. Error bar showed mean ± SD (\*p value ≤ 0.05). **e** For infections showing a significant difference in infection from **c** and **d**, the supernatants at 0 h (input virus; 0 h) and 24 h post infection (24 h) were assayed for virus titer by standard plaque assay. **f** HEK293T/17 cells were infected with DENV 2 at MOI 2 or 0.01 and treated with increasing concentrations of resveratrol or treated with vehicle and at 24 h post infection supernatants were assayed for virus titer by standard plaque assay. All experiments were undertaken independently in triplicate. Error bar showed mean ± SD (\*p value ≤ 0.05, \*\*p value ≤ 0.01)

### Melatonin {#Sec11}

Melatonin (*N*-acetyl-5-methoxy tryptamine) is a natural hormone that is primarily produced by the pineal gland and regulates the circadian rhythm \[[@CR13]\], and exogenous melatonin is often administered to adjust the sleep--wake cycle \[[@CR14]\]. However, studies have shown that melatonin also has significant antiviral effects. Melatonin has been shown to have some effects in animal models of Venezuelan equine encephalitis virus \[[@CR15], [@CR16]\], Semliki Forest virus \[[@CR17]\], West Nile virus \[[@CR17]\], respiratory syncytial virus \[[@CR18]\] and its use has been proposed in humans infected with Ebola virus \[[@CR19]\]. In this study, melatonin showed a slight proviral effect upon DENV 2 infection in HEK293T/17 cells (Fig. [1](#Fig1){ref-type="fig"}c) under conditions of the lowest MOI used, and the highest concentration of melatonin, but no effect was seen in HepG2 cell (Fig. [1](#Fig1){ref-type="fig"}d).

### α-Tocopherol {#Sec12}

Vitamin E refers to compounds classed as both tocopherols and tocotrienols. There are four vitamin E tocopherols, termed α-, β-, γ- and δ-, and while γ-tocopherol is the most abundant form of vitamin E, α-tocopherol is the second most abundant and the most biologically active form \[[@CR20]\]. Vitamin E has well known antioxidant properties, through its ability to donate a hydrogen group from its free hydroxyl group to the free radical, with the generation of a stable free radical form of vitamin E. However, a number of non-antioxidant activities of vitamin E have been demonstrated \[[@CR21]\]. α-Tocopherol has been reported to have some effects in dengue patients \[[@CR22]\] and has proposed benefits for influenza virus A infection \[[@CR23]\], as well as possible activity against hepatitis B \[[@CR24]\] and C \[[@CR25]\]. In this study, α-tocopherol showed proviral effects, particularly in HEK293T/17 cells (Fig. [2](#Fig2){ref-type="fig"}c), where the percentage of infection was increased significantly under most condition combinations tested. However, only a small effect was seen in HepG2 cells under conditions of the highest concentration and lowest MOI tested (Fig. [2](#Fig2){ref-type="fig"}d).

### Acetyl-[l]{.smallcaps}-carnitine {#Sec13}

Acetyl-[l]{.smallcaps}-carnitine (ALCAR) is the acetylated form of [l]{.smallcaps}-carnitine a molecule naturally produced by the body and the acetylated form of [l]{.smallcaps}-carnitine is able to cross the blood brain barrier \[[@CR26]\]. [l]{.smallcaps}-Carnitine functions primarily to transport activated long chain fatty acids into mitochondria for degradation by β-oxidation, and β-oxidation has been proposed to be important in DENV replication \[[@CR27]\]. In addition, [l]{.smallcaps}-carnitine has been shown to have activity against hepatitis C virus \[[@CR28]\]. In this study, ALCAR was shown to have no effect on DENV 2 infection in either cell line (Additional file [1](#MOESM1){ref-type="media"}: Figure S1C, D).

### Folic acid {#Sec14}

Folic acid is the synthetic form of vitamin B9, while folate is the naturally occurring form found in food. Folic acid is essential for nervous system development, and is a commonly administered supplement to pregnant mothers to prevent neural tube defects \[[@CR29]\]. Folic acid is also important in the synthesis of RNA and DNA, and is particularly important in rapidly dividing cells \[[@CR30]\]. Folic acid additionally plays a role in the formation of red blood cells \[[@CR30]\]. Folic acid has not previously been explored for anti-viral activity, although the metabolically active form of folic acid, folinic acid has been described as having pro-flaviviral effects through the thymidine synthesis pathway \[[@CR31]\]. In this study, folic acid had little effect upon DENV 2 infection in either cell line (Additional file [2](#MOESM2){ref-type="media"}: Figure S2C, D), although a slight proviral effect was seen at the highest concentration examined in HepG2 cells (Additional file [2](#MOESM2){ref-type="media"}: Figure S2D).

### Resveratrol {#Sec15}

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a hydroxylated derivative of stilbene, and a phytoalexin which is produced in response to pathogen attack in some plants. It is found in nature in several foods including grapes and blueberries \[[@CR32]\]. Considerable attention has been focused on resveratrol for potential anti-cancer \[[@CR33]\], anti-obesity \[[@CR34]\], anti-neurodegeneration \[[@CR35]\] and cardio-protective activities \[[@CR32]\]. Studies have shown that resveratrol has activity against a number of viruses including HIV \[[@CR36]\], Middle East respiratory syndrome coronavirus (MERS-CoV) \[[@CR37]\], influenza A virus \[[@CR38]\], poxvirus \[[@CR39]\] and enterovirus 71 \[[@CR40]\].

As noted earlier, resveratrol showed significant cytotoxicity in HEK293T cells, but that HepG2 cells were somewhat less sensitive to the cytotoxic effects of the compound (Fig. [3](#Fig3){ref-type="fig"}a, b). However, infection with DENV 2 in the presence of resveratrol (at 25 and 50 μM) in HEK293T/17 cells showed a significant reduction in the level of infection (Fig. [3](#Fig3){ref-type="fig"}c), while a slight increase in infection levels was seen in HepG2 cells (Fig. [3](#Fig3){ref-type="fig"}d) with the lowest MOI and 50 μM resveratrol. We observed some background in the flow cytometry with resveratrol (Fig. [3](#Fig3){ref-type="fig"}) and this might be related to the protein binding ability of resveratrol \[[@CR41]\]. However, subtraction of the background did not alter the result. To further investigate the effect of resveratrol in DENV 2 infection, the effect on virus production was determined by standard plaque assay. The virus titer was determined at 0 h (input virus) and at 24 h post infection. The results (Fig. [3](#Fig3){ref-type="fig"}e) showed that, consistent with the reduction in the level of cellular infection (Fig. [3](#Fig3){ref-type="fig"}c), there was a reduction in the level of virus produced with treatment with resveratrol in HEK293T/17 cells at 24 h post infection, but not in HepG2 cells (Fig. [3](#Fig3){ref-type="fig"}e). The reduction of virus output observed was the order of approximately 1log~10~. To determine the EC~50~ of resveratrol on virus production, the experiment was repeated in HEK293T/17 cells with concentrations of 0, 0.1, 1, 5, 10, 25 and 50 μM resveratrol. Results of the standard plaque assay are shown in Fig. [3](#Fig3){ref-type="fig"}f. The EC~50~ value was determined as 24.37 μM. Finally, the experiment was undertaken at a lower MOI of 0.01. Results (Fig. [3](#Fig3){ref-type="fig"}f) showed a dose dependent reduction of virus production, with an EC~50~ value of 11.37 μM. While the reduction in level of infection and virus output is significant in HEK293T/17 cells, it compares poorly to other natural compounds such as andrographolide, which reduces DENV 2 virus output by 2.5log~10~ \[[@CR11]\].

Conclusion {#Sec16}
----------

These results suggest that some commonly taken natural compounds may have beneficial effects on DENV infection, but that others may potentially add to the disease burden.

Limitations {#Sec17}
===========

Only one of the four DENV serotypes was examined.Cytotoxic effects limited the concentration test range of compounds.
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 {#Sec18}

**Additional file 1.** Effect of acetyl-[l]{.smallcaps}-carnitine on DENV2 infection of HEK293T/17 and HepG2 cells. **Additional file 2.** Effect of folic acid on DENV2 infection of HEK293T/17 and HepG2 cells.
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